Diabetes, obesity & metabolismFeb 10, 2021

Switching to iGlarLixi versus continuing daily or weekly GLP-1 receptor drugs in people with type 2 diabetes not well controlled, analyzed by blood sugar levels and prior medication use

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Apr 5, 2026

Abstract

Switching to iGlarLixi resulted in significantly greater reductions in HbA1c compared to continuing GLP-1 RA therapy at Week 26.

Participants switching to iGlarLixi had a higher proportion achieving HbA1c levels below 7% compared to those continuing GLP-1 RA treatment.
Significant reductions in fasting plasma glucose and 2-hour postprandial plasma glucose were observed with iGlarLixi, regardless of previous GLP-1 RA regimen.
Rates of hypoglycaemia were low but slightly elevated in the iGlarLixi group across all subgroups.
Modest weight gain was noted in individuals switched to iGlarLixi, independent of prior GLP-1 RA treatment.

Simplified

AIM: In people with type 2 diabetes (T2D) requiring intensification beyond glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well-tolerated in the LixiLan-G trial. This exploratory analysis of LixiLan-G assessed the efficacy and safety of switching to iGlarLixi versus continuing GLP-1 RA therapy, stratified by screening HbA1c level (≥7.0 to ≤7.5 %; >7.5 to ≤8.0 %; >8.0 to ≤9.0 % [≥53 to ≤58 mmol/mol; >58 to ≤64 mmol/mol; >64 to ≤75 mmol/mol]) and previous GLP-1 RA regimen at screening (once/twice daily or once weekly).

MATERIALS AND METHODS: Endpoints for all subgroups included: change in HbA1c, achievement of HbA1c <7 % and hypoglycaemia events. Adverse events and changes in fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (PPG), 2-hour PPG excursion and weight were analysed according to previous GLP-1 RA regimen.

RESULTS: Switching to iGlarLixi in all subgroups resulted in significantly greater reductions in HbA1c and proportions of participants reaching HbA1c <7 % (including with no documented hypoglycaemia) at Week 26 compared with continued GLP-1 RA treatment. Switching to iGlarLixi also led to significantly greater reductions in FPG, 2-hour PPG, and 2-hour PPG excursion, irrespective of previous GLP-1 RA regimen. Rates of hypoglycaemia were low, but slightly higher in those who switched to iGlarLixi for all subgroups. Modest weight gain was seen with iGlarLixi, irrespective of previous GLP-1 RA regimen.

CONCLUSIONS: Switching to iGlarLixi improved glycaemic control, regardless of screening HbA1c or previous GLP-1 RA type, offering a simple, efficacious and well-tolerated treatment intensification option for people with T2D inadequately controlled by GLP-1 RAs and OADs.

Key numbers

0.6%

HbA1c Reduction

Mean reduction in HbA1c from screening to Week 26 for those switching to iGlarLixi.

53% to 69%

HbA1c Target Achievement

Proportion of participants achieving HbA1c <7% at Week 26 after switching to iGlarLixi.

+2.1 kg

Weight Change

Mean weight change from baseline to Week 26 for participants switching to iGlarLixi.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

J.R. has been a consultant for Applied Therapeutics, Boehringer Ingelheim, Eli Lilly, Intarcia, Janssen, Novo Nordisk, Oramed and Sanofi, and has received grant/research support from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Genentech, GlaxoSmithKline, Intarcia, Janssen, Lexicon, Merck, Novo Nordisk, Oramed, Pfizer and Sanofi. L.B. has been a consultant for AstraZeneca, Gilead Sciences, Janssen, Merck, Novo Nordisk and Sanofi, has received grant/research support (including to his institution) from Janssen, Lexicon, Merck, Novo Nordisk and Sanofi, and has been a speaker for Janssen, Novo Nordisk and Sanofi. V.R.A. has received clinical trial/research support from Applied Therapeutics, Fractyl/Premier, Novo Nordisk and Sanofi, has been a consultant for Applied Therapeutics, Novo Nordisk and Sanofi, and her spouse is an employee of Janssen. J.F. has been a consultant for Boehringer Ingelheim, Johnson & Johnson, Eli Lilly, Merck, Novo Nordisk and Sanofi, has received grant/research support from AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Sanofi and Theracos, and has been a speaker for Merck and Sanofi. E.S., C.J. and E.N. are employees of Sanofi. S.D.P. has received grant/research support from AstraZeneca, Boehringer Ingelheim, Merck and Novartis, and honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Mundipharma, Novartis, Novo Nordisk, Sanofi, Servier and Takeda.

PubMed

Switching to iGlarLixi versus continuing daily or weekly GLP-1 receptor drugs in people with type 2 diabetes not well controlled, analyzed by blood sugar levels and prior medication use

Abstract

Key numbers

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief